Medicus Pharma Gains UAE Approval for Phase 2 Basal Cell Carcinoma Trial

Medicus Pharma has received approval from the UAE Department of Health to begin a Phase 2 clinical trial (SKNJCT-004) to non-invasively treat basal cell carcinoma (BCC) of the skin using its topical formulation D-MNA. This randomized, double-blind, placebo-controlled study will enroll 36 patients across four UAE medical centers, including Cleveland Clinic Abu Dhabi, and evaluate two doses of D-MNA (100μg and 200μg) against a placebo. The 200μg dose was established as safe and well-tolerated in a prior Phase 1 trial (SKNJCT-001), where six of 13 participants experienced complete clearance of BCC lesions. This new UAE study complements Medicus' ongoing US-based Phase 2 trial, SKNJCT-003, which has shown promising interim results with over 60% clinical clearance, leading to an expansion of participant numbers and trial sites into Europe. The company continues to advance its strategy to develop non-invasive skin cancer treatments globally using its patented dissolvable microneedle patch technology. Despite positive clinical progress, Medicus faces challenges related to its financial position, including lack of revenue and ongoing losses, which contribute to cautious investor sentiment.